4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which is a new drug indicated for amyotrophic lateral sclerosis, often called Lou Gehrig’s Disease. 

But, there are also pricing and reimbursement issues the drug will face as its sponsor, Amylyx Pharmaceuticals, pursues market uptake.

Read Forbes article